Please use this identifier to cite or link to this item:
https://mnclhd.intersearch.com.au/mnclhdjspui/handle/123456789/147
Title: | IgM multiple myeloma with an extremely rare non-aggressive presentation: A case report |
Authors: | Greuter, T. Browne, M. Dommann-Scherrer, C. Binder, D. Renner, C. Kapp, U. |
MNCLHD Author: | Browne, Martin |
Issue Date: | Oct-2016 |
Citation: | Oncology letters . 2016 Oct;12(4):2801-2803. doi: 10.3892/ol.2016.5034. |
Abstract: | In the present study, the case of a 41-year-old man with immunoglobulin (Ig)M multiple myeloma (MM) that presented with an unusually non-aggressive clinical course who has survived for >9 years to date, is presented. Initial diagnosis of symptomatic MM was established according to the International Myeloma Working Group consensus statement and guidelines. Due to the mild symptoms, no therapy was administered and the patient was closely followed up. Eight years after initial diagnosis, clinical, morphological and genetic progression occurred with the development of hypercalcemia, progressively deteriorating polyneuropathy, clonal expansion of plasma cells up to 50% of hematopoietic cells and demonstration of the typical t(11;14) translocation (Ig heavy chain locus rearrangement). Subsequently, 4 cycles of induction chemotherapy with velcade, cyclophosphamide and dexamethasone, were administered. At the time of writing, the patient remained alive in generally good health. To the best of our knowledge, with a survival time of >9 years, this case reports the longest survival time of an IgM MM patient to date, which contradicts previous evidence that suggests IgM MM exhibits an aggressive clinical course. |
URI: | https://mnclhd.intersearch.com.au/mnclhdjspui/handle/123456789/147 |
Keywords: | Multiple Myeloma;Immunoglobulin M |
Appears in Collections: | Oncology / Cancer |
Files in This Item:
File | Size | Format | |
---|---|---|---|
IgM multiple myeloma with an extremely rare.pdf | 583.45 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.